Publications

Bone Marrow Aspirate Concentrate May Decrease Reoperation in Osteochondral Allograft Transplantation: A Prospective, Randomized, Double Blind Investigation

Purpose: To evaluate whether adding bone marrow aspirate concentrate (BMAC) to osteochondral allograft transplantation improves graft integration, patient-reported outcomes, or reduces reoperation rates compared to standard allografts. 

Summary:

• This prospective, randomized, double-blind trial found patients who received BMAC treated OCAs were less likely to need subsequent surgeries for graft debridement or revision. 
• OCAs treated with BMAC showed a trend toward reduced large cyst formation and were more likely to show small cystic changes. 
   

JRF Takeaways: BMAC is a biologic adjunct that may enhance outcomes following osteochondral allograft (OCA) transplantation. In this study, the addition of BMAC was associated with a reduced need for subsequent debridement and revision surgeries. Postoperative imaging revealed a greater incidence of small cystic changes in the BMAC group, with a trend toward reduced formation of larger cysts. Patients who received BMAC also demonstrated a trend toward improved KOOS JR scores at both 1- and 2-year follow-up. Further studies with larger sample sizes are warranted to further elicit these differences. 

Click here for the complete abstract. 

Authors: Adam B. Yanke, MD, PhD, Navya Dandu, MD, Blake M. Bodendorfer, MD, Nicholas A. Trasolini, MD, Mario Hevesi, MD, PhD, Tristan J. Elias, BA, Erik Haneberg, BS, Reem Y. Darwish, BS, Athan Zavras, MD, Brian Forsythe, MD, Brian J. Cole, MD, MBA

Published: The Journal of Arthroscopic and Related Surgery

Institution: Rush University Medical Center, Chicago, Illinois, Alleghany General Hospital, Pittsburgh, Pennsylvania, Wake Forest Baptist Health, Winston-Salem, North Carolina, and Mayo Clinic, Rochester, Minnesota.